IGF2BP2 and neoplasm: As shown in Figure 4(a–c), in the group treated with the PD-L1 inhibitor or transplanted with the shRNA-IGF2BP2 cells, body weight and tumor volume was relatively lower than the control group or shRNA-NC group, respectively.